

Dr. Martens plc
Notification of transaction by Person Closely Associated with a PDMR

Dr. Martens plc (the ‘Company’) announces that on 26 September 2024 the following transaction in the Company’s ordinary shares was undertaken by a person closely associated with a director / person discharging managerial responsibility (‘PDMR’).

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1. Details of PDMR / person closely associated with them			
a)	Name	Katie Wilson	
2. Reasons for the notification			
a)	Position / status	Person Closely Associated with Giles Wilson, Chief Financial Officer and PDMR	
b)	Initial notification / amendment	Initial notification	
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Full name of the entity	Dr. Martens plc	
b)	Legal Entity Identifier code	213800QPT8YM6NQZPH28	
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument Identification Code	Ordinary Shares of GBP 0.01 each ISIN: GB00BL6NGV24	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.554	30,000
d)	Aggregated information Aggregated volume Price	N/A – single transaction	
e)	Date of the transaction	26 September 2024	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUNVURSBUKUAR